CEACAM5 and pancreatic adenocarcinoma: These findings may indicate an opportunity to utilize routine clinical biomarkers such as CA 19‐9 and CEA to enrich for possibility of underlying occult pancreatic adenocarcinoma in patients with APUE as there appears to be a low likelihood of confounding from acute pancreatitis per se.